Table 3.
Characteristics of 23 Patients with HMPV LRTD, According to Ribavirin Therapy
| Characteristic | Treated with Ribavirin (n = 10) | No Ribavirin (n = 13) |
|---|---|---|
| Underlying disease | ||
| Acute leukemia | 4 (40%) | 4 (31%) |
| HD/MM/NHL | 3 (30%) | 6 (46%) |
| CML | 1 (10%) | 0 (0%) |
| CLL | 0 (0%) | 3 (23%) |
| Other | 2 (20%) | 0 (0%) |
| Donor type | ||
| Matched related | 1 (10%) | 1 (8%) |
| Mismatched/unrelated | 5 (50%) | 7 (55%) |
| Autologous | 1 (10%) | 2 (15%) |
| Pretransplant | 3 (30%) | 3 (22%) |
| Acute GVHD∗ | 3 (50%) | 7 (88%) |
| Median days post-HCT∗ | 18 | 124 |
| Ventilated at diagnosis | 3 (30%) | 2 (15%) |
HD indicates Hodgkin disease; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; GVHD, graft-versus-host disease.
∗
Allogeneic recipients only.